• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

FDA OKs drug for heart transplant patients

Posted on: Thursday, 30 March 2006, 22:02 CST

WASHINGTON (Reuters) - U.S. health regulators on Thursday approved the first new drug in nearly a decade to prevent organ rejection in heart transplant patients.

The drug, Astellas Pharma Inc.'s Prograf, is already cleared to prevent rejection of liver and kidney transplants. But the U.S. Food and Drug Administration said the wider approval would help the more than 2,000 patients who get new hearts each year.

"The doctors who perform approximately 2,200 heart transplants in the U.S. each year will now have a new option for enhancing successful outcomes," said Dr. Steven Galson, head of the FDA's Center for Drug Evaluation and Research.

Prograf works by suppressing the body's immune system, which can attack new organs it senses as foreign objects.

In one study of U.S. patients, 93.5 percent of patients and their new hearts survived one year after transplant. That rate was similar to what was seen in patients given an older drug, cyclosporine.

Side effects of Prograf treatment included an increased risk of kidney impairment, infection and diabetes, the FDA said. Use of all immune-suppressing transplant drugs also can increase the risk of cancer when they are used in combination.

Prograf's main chemical ingredient, tacrolimus, is also used in the Japanese company's eczema cream Protopic.

Source: REUTERS

More News in this Category